<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37338820</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-6551</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Current opinion in neurology</Title><ISOAbbreviation>Curr Opin Neurol</ISOAbbreviation></Journal><ArticleTitle>Susceptibility and disease modifier genes in amyotrophic lateral sclerosis: from genetic associations to therapeutic implications.</ArticleTitle><Pagination><StartPage>365</StartPage><EndPage>370</EndPage><MedlinePgn>365-370</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/WCO.0000000000001178</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW">Amyotrophic lateral sclerosis (ALS) is a severe disease characterized by the degeneration of motor neurons. Large-scale genetic studies have now identified over 60 genes that are associated with ALS, which in large part have also been functionally characterized. The purpose of this review is to outline how these advances are being translated into novel therapeutic strategies.</AbstractText><AbstractText Label="RECENT FINDINGS">The emergence of techniques that allow the specific therapeutic targeting of a (mutant) gene, in particular antisense oligonucleotide therapy (ASOs), have led to the first successful gene therapy for SOD1-ALS and multiple other gene-targeted trials are underway. This includes genetic variants that modify the disease phenotype as well as causal mutations.</AbstractText><AbstractText Label="SUMMARY">Technological and methodological advances are enabling researchers to unravel the genetics of ALS. Both causal mutations and genetic modifiers are viable therapeutic targets. By performing natural history studies, the phenotype-genotype correlations can be characterized. In conjunction with biomarkers for target engagement and international collaboration, this makes performing gene-targeted trials ALS feasible. The first effective treatment has now been developed for SOD1-ALS and, with multiple studies underway, it seems realistic that more therapies will follow.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Willemse</LastName><ForeName>Sean W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center Rudolf Magnus, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Opin Neurol</MedlineTA><NlmUniqueID>9319162</NlmUniqueID><ISSNLinking>1350-7540</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060045" MajorTopicYN="N">Genes, Modifier</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>
<i>M.Av.Es. consulted for Biogen, and has received travel grants from Shire (formerly Baxalta), performs work as a medical monitor for an ongoing trial from Ferrer (NCT05178810).</i>
</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>20</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>20</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37338820</ArticleId><ArticleId IdType="pmc">PMC10328529</ArticleId><ArticleId IdType="doi">10.1097/WCO.0000000000001178</ArticleId><ArticleId IdType="pii">00019052-990000000-00081</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. . Amyotrophic lateral sclerosis. Lancet 2017; 390:2084&#x2013;2098.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, et al. . Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Jr, Bosco DA, Leclerc AL, et al. . Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009; 323:1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, et al. . TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008; 319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortobagyi T, et al. . Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009; 323:1208&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher EMC, Greensmith L, Malaspina A, et al. . Opinion: more mouse models and more translation needed for ALS. Mol Neurodegener 2023; 18:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10161557</ArticleId><ArticleId IdType="pubmed">37143081</ArticleId></ArticleIdList></Reference><Reference><Citation>Du H, Huo Z, Chen Y, et al. . Induced pluripotent stem Cells and their applications in amyotrophic lateral sclerosis. Cells 2023; 12:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10047679</ArticleId><ArticleId IdType="pubmed">36980310</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Brown RH, Jr. Finding a treatment for ALS: will gene editing cut it? N Engl J Med 2018; 378:1454&#x2013;1456.</Citation><ArticleIdList><ArticleId IdType="pubmed">29641956</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal S. The evolution of antisense oligonucleotide chemistry: a personal journey. Biomedicines 2021; 9:503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8147625</ArticleId><ArticleId IdType="pubmed">34063675</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 2018; 14:9&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">29192260</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Mercuri E, Darras BT, et al. . Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017; 377:1723&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Cudkowicz ME, Genge A, et al. . Trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 2022; 387:1099&#x2013;1110.</Citation><ArticleIdList><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunckley T, Huentelman MJ, Craig DW, et al. . Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med 2007; 357:775&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">17671248</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, van der Spek RAA, Bakker MK, et al. . Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet 2021; 53:1636&#x2013;1648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, Shatunov A, Dekker AM, et al. . Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet 2016; 48:1043&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Spek RAA, van Rheenen W, Pulit SL, et al. . The project MinE databrowser: bringing large-scale whole-genome sequencing in ALS to researchers and the public. Amyotroph Lateral Scler Frontotemporal Degener 2019; 20:432&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7893599</ArticleId><ArticleId IdType="pubmed">31280677</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, Lasseigne BN, Petrovski S, et al. . Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 2015; 347:1436&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Veldink JH, Saris CG, et al. . Genome-wide association study identifies 19p13.3 (UNC13A) and 9p212 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet 2009; 41:1083&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita M, Al-Chalabi A, Andersen PM, et al. . A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 2006; 66:839&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16421333</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. . Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna KP, van Doormaal PT, Dekker AM, et al. . NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet 2016; 48:1037&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5560030</ArticleId><ArticleId IdType="pubmed">27455347</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Jr, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med 2017; 377:1602.</Citation><ArticleIdList><ArticleId IdType="pubmed">29045202</ArticleId></ArticleIdList></Reference><Reference><Citation>Willemse SW, Harley P, van Eijk RPA, et al. . UNC13A in amyotrophic lateral sclerosis: from genetic association to therapeutic target. J Neurol Neurosurg Psychiatry 2023; jnnp-2022-330504.</Citation><ArticleIdList><ArticleId IdType="pubmed">36737245</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL, Wilkins OG, Keuss MJ, et al. . TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 2022; 603:131&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, et al. . TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature 2022; 603:124&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, et al. . Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010; 466:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, et al. . Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 2017; 544:367&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali T, Self W, Liu J, et al. . Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J Neurol Neurosurg Psychiatry 2017; 88:99&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5136332</ArticleId><ArticleId IdType="pubmed">27261500</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, et al. . Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med 2022; 28:104&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8799464</ArticleId><ArticleId IdType="pubmed">35075293</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilliott AA, Al Nasser A, Elnagheeb M, et al. . Clinical testing panels for ALS: global distribution, consistency, and challenges. Amyotroph Lateral Scler Frontotemporal Degener 2023; 1&#x2013;16. doi: 10.1080/21678421.2023.2173015. [Online ahead of print].</Citation><ArticleIdList><ArticleId IdType="pubmed">36896705</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>